Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board

 
Press Release 
Nicox Appoints Christine Placet to Board of Directors; Michele 
 Garufi steps down from Board 
------------------------------------------------------------------------------ 
 
 
 --    Christine Placet is CFO of Theranexus, and was 
       formerly CEO of Horama and Trophos 
 
 --    Michele Garufi, former Chairman and CEO of Nicox, 
       hands over his Board position after over more than 25 
       years at the company he co-founded 
 
 --    The Nicox Board has now been entirely renewed to 
       bring in the expertise to support the Company's 
       strategic direction going forward 
 
 September 4(th) , 2024 -- release at 7:30 am CET 
 Sophia Antipolis, France 
 Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international 
 ophthalmology company, today announced that Michele Garufi is 
 stepping down as a member of the Board of Directors. The Board 
 has appointed Christine Placet, a deeply experienced CEO and 
 financial leader in the biotech industry, as a new Board member. 
 The renewal of the Nicox Board brings the appropriate expertise 
 to support the Company's strategic direction going forward. 
 "I am delighted to welcome Christine Placet to Nicox as a new 
 Board member. I had the pleasure of working with Christine during 
 our time at Trophos, where she played a pivotal role as CFO. 
 Her expertise, strategic vision, and leadership in biotech are 
 invaluable assets to Nicox. I look forward to working closely 
 with her again as we continue to drive the business forward, 
 with the focus on our de-risked compound NCX 470, moving towards 
 topline results from the second pivotal Phase 3 trial, Denali, 
 in H2 2025," said Damian Marron, Chairman of Nicox. 
 "On behalf of the Board and of Nicox, past and present, I would 
 like to express my heartfelt gratitude to Michele Garufi for 
 his dedicated and unstinting service to the company. Nicox has 
 benefited from Michele's vision, business acumen, scientific 
 expertise and leadership for nearly 30 years, as we have sought 
 to develop innovative solutions to help maintain vision and improve 
 ocular health. We all wish Michele the very best for the future." 
 Michele Garufi, Co-Founder of Nicox, who served as CEO and Chairman 
 until 2022 commented: "After many years of service at Nicox, 
 this is the right time to hand over to a new generation of leadership. 
 With Damian Marron appointed Chairman and Gavin Spencer as CEO 
 earlier this year, we have a talented and dynamic leadership 
 team in place who have led companies through critical phases 
 of development and executed major financial transactions. I am 
 therefore confident that Nicox is in very capable hands. I wish 
 them every further success as they aim to deliver on the potential 
 of NCX 470 to improve treatment of glaucoma." 
 Christine Placet joins Nicox with a distinguished career in the 
 biotech industry. She started as an auditor at Ernst & Young 
 and then built up extensive experience of financial leadership 
 in small- and medium- sized companies. In 2004, she joined the 
 biotech company Trophos as Chief Financial Officer, later becoming 
 Chief Executive Officer. Under her leadership, Trophos was acquired 
 by Roche for EUR470 million in 2015. She then became CEO of Horama 
 (now Coave Therapeutics) in 2016, successfully leading funding 
 rounds and advancing a key product into development. In 2021, 
 she transitioned into consulting and joined Theranexus as CFO 
 in April 2024. She is a graduate of Kedge Business School. 
About Nicox 
Nicox SA is an international ophthalmology company developing 
 innovative solutions to help maintain vision and improve ocular 
 health. Nicox's lead program in clinical development is NCX 470 
 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost 
 eye drop, for lowering intraocular pressure in patients with 
 open-angle glaucoma or ocular hypertension. Nicox generates revenue 
 from VYZULTA$(R)$ in glaucoma, licensed exclusively worldwide to 
 Bausch + Lomb, and ZERVIATE(R) in allergic conjunctivitis, licensed 
 in multiple geographies, including to Harrow, Inc. in the U.S., 
 and Ocumension Therapeutics in the Chinese and in the majority 
 of Southeast Asian markets. 
 Nicox, headquartered in Sophia Antipolis, France, is listed on 
 Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the 
 CAC Healthcare index. 
 For more information www.nicox.com 
Analyst coverage 
 
 H.C. Wainwright & Co Yi Chen New York, 
 U.S. 
The views expressed by analysts in their coverage of Nicox are 
 those of the author and do not reflect the views of Nicox. Additionally, 
 the information contained in their reports may not be correct 
 or current. Nicox disavows any obligation to correct or to update 
 the information contained in analyst reports. 
Contacts 
Nicox                                  Media / Investors Sophie Baumont 
 Gavin Spencer                         Cohesion Bureau +33 6 27 74 74 49 
 Chief Executive Officer               sophie.baumont@cohesionbureau.com 
 T +33 (0)4 97 24 53 00 
 communications@nicox.com 
------------------------------------- 
Disclaimer 
The information contained in this document may be modified without 
 prior notice. This information includes forward-looking statements. 
 Such forward-looking statements are not guarantees of future 
 performance. These statements are based on current expectations 
 or beliefs of the management of Nicox S.A. and are subject to 
 a number of factors and uncertainties that could cause actual 
 results to differ materially from those described in the forward-looking 
 statements. Nicox S.A. and its affiliates, directors, officers, 
 employees, advisers or agents, do not undertake, nor do they 
 have any obligation, to provide updates or to revise any forward-looking 
 statements. 
 Risks factors which are likely to have a material effect on Nicox's 
 business are presented in section 3 of the "Rapport Annuel 2023" 
 which is available on Nicox's website (www.nicox.com). 
 Finally, this press release may be drafted in the French and 
 English languages. If both versions are interpreted differently, 
 the French language version shall prevail. 
Nicox S.A. 
 Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue 
 Evariste Galois, 06410 Biot, France 
 T +33 (0)4 97 24 53 00 
 

Attachment

   -- EN_NewBoardMemberChristinePlacet_PR_FINAL 

(END) Dow Jones Newswires

September 04, 2024 01:30 ET (05:30 GMT)